Clinical Trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HS-10510 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels. This study will consist of three parts (Parts A，B and C). 32 subjects have been planned for Part A and up to 36 subjects for Part B and 20 subjects for Part C.
Trial Details
NCT Number NCT07001787
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Dyslipidemia
Enrollment 88 participants
Start Date 2025-06
Primary Completion 2026-02 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-06-03